Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Wound Care ; 33(Sup4a): xcix-cx, 2024 Apr 02.
Artículo en Inglés | MEDLINE | ID: mdl-38588056

RESUMEN

Metal-based nanoparticles (MNPs) are promoted as effective compounds in the treatment of bacterial infections and as possible alternatives to antibiotics. These MNPs are known to affect a broad spectrum of microorganisms using a multitude of strategies, including the induction of reactive oxygen species and interaction with the inner structures of the bacterial cells. The aim of this review was to summarise the latest studies about the effect of metal-based nanoparticles on pathogenic bacterial biofilm formed in wounds, using the examples of Gram-positive bacterium Staphylococcus aureus and Gram-negative bacterium Pseudomonas aeruginosa, as well as provide an overview of possible clinical applications.


Asunto(s)
Nanopartículas , Infecciones Estafilocócicas , Infección de Heridas , Humanos , Biopelículas , Staphylococcus aureus , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Pseudomonas aeruginosa , Nanopartículas/uso terapéutico , Infección de Heridas/tratamiento farmacológico , Infección de Heridas/microbiología
2.
Antiviral Res ; 127: 1-9, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26769398

RESUMEN

We have demonstrated the influence of cerium dioxide nanoparticles on the immunogenicity of the influenza vaccine on an example of liquid split inactivated Vaxigrip vaccine. Antibody titers were analyzed using the hemagglutination inhibition (HI) assay. Seroprotection, seroconversion, the geometric mean titers (GMTs) and the factor increase (FI) in the GMTs were calculated. The effect of nano-ceria surface stabilizer on the enhancement of immunogenicity was shown. The vaccine modified by citrate-stabilized nano-ceria, in contrast to a non-modified Vaxigrip vaccine, did not provide an adequate level of seroprotection, and seroconversion after vaccination was 66.7% on days 49-63 for virus strain А(H1N1) and 100% on day 49 for virus strain B/Yamagata. For the low immunogenic influenza B virus, the rise in antibody titers (GMT/IF) was 24.38/3.28 after the first injection and 50.40/6.79 on day 49. For the vaccine modified by non-stabilized nano-ceria, for all virus strains under study, on day 63, upon immunization notable levels of seroprotection, seroconversion and GMT/IF were registered (higher than for the non-modified Vaxigrip vaccine). The successful attempt to modify the influenza vaccine demonstrates the possible ways of increasing the specific activity of vaccines using nano-ceria.


Asunto(s)
Cerio/farmacología , Subtipo H1N1 del Virus de la Influenza A/inmunología , Subtipo H3N2 del Virus de la Influenza A/inmunología , Virus de la Influenza B/inmunología , Vacunas contra la Influenza/inmunología , Nanopartículas/administración & dosificación , Animales , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Formación de Anticuerpos/efectos de los fármacos , Formación de Anticuerpos/inmunología , Cerio/química , Cerio/inmunología , Femenino , Pruebas de Inhibición de Hemaglutinación/métodos , Vacunas contra la Influenza/química , Vacunas contra la Influenza/farmacología , Ratones , Microscopía Electrónica de Transmisión , Nanopartículas/química , Vacunas de Productos Inactivados/química , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA